How to set your ##dining ##table for ##guests

How to set your dining table for guests

Have a fancy dinner table don’t know how to set it for formal occasions? Here are a few tips on how to make it look aesthetically nice…

Go for crisp linens: If you want to spread a table cloth, make sure it’s in linen, as this material hangs well on any surface. You can also place napkins and table mats in the same material.
Invest in Chinaware: Though expensive, the look that dainty Chinaware provides on a table during a special or festive occasion is unmatched. Invest in a set that can be used sparingly whenever you have guests over.
A sleek centerpiece: If you have a big dining table, you can decorate it with a creative centerpiece, complementing it with the decor or even with the cuisine that you’re serving. From candles and potpourri to bulbs.
Name cards on the table: For a large, formal dinner party, if you’ve invited many people, you can even keep names cards on the table, so that people know where they are expected to sit, without causing any chaos and confusion.

Top 75 #companies #spent Rs 4,000 crore on #CSR in 2015

Big CSR spenders include Reliance Industries with Rs 760 crore, ONGC with Rs 495 crore, Infosys with Rs 239 crore, NTPC with Rs 205 crore and TCS with Rs 220 crore, according to company filings.

The country’s top 75 companies spent more than Rs 4,000 crore towards corporate social responsibility in the last fiscal, the first year after the government mandated bigger companies to give away a part of their profits for social work, early estimates of the government show.

Big CSR spenders include Reliance IndustriesBSE -0.31 % with Rs 760 crore, ONGC with Rs 495 crore, InfosysBSE 3.13 % with Rs 239 crore, NTPCBSE -0.08 % with Rs 205 crore and TCS with Rs 220 crore, according to  ..

Dr Reddy’s acquires Habitrol brand

"With this closure, the company has assumed responsibility for the product and will commence shipments of the product in the market shortly," DRL said.

City-based drugmaker Dr Reddy’s Laboratories has acquired Habitrol brand, a nicotine replacement therapy transdermal patch, from NovartisBSE -0.74 % Consumer Health Inc.

According to a statement issued by the drug major, the acquisition of Habitrol brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc was done following issuance of the proposed consent order from the US Federal by TotalPlu ..

Rouble fallout: Dr Reddy’s, Ranbaxy’s profit in trouble

Depreciation of the russian currency poses a risk to the profitability of Indian pharma companies such as Dr Reddy’s, Glenmark and ranbaxy. Russia, a key market for these companies, contributes 5% of overall Indian pharma exports.
RussiaCIS accounts for 10% of overall sales of companies like Dr Reddy’s, Glenmark, Ranbaxy , IPCA and Torrent. In the September quarter, they began reporting that the Russian currency devaluation was hurting business. This could worsen.

Political crisis in Russia and weakening crude prices have resulted in sharp rouble depreciation against the US dollar (83% since March 2014). Analysts say an unchecked rouble slide would hurt profitability, especially if rupee holds stable (versus USD).

dr. reddys and Glenmark could take a hit as Russia CIS constitutes 9-15% of their total revenues. But the impact on Torrent and IPCA would be nominal, owing to lower sales RussiaCIS, Rajat Rajgarhia, MD institutional equities, Motilal Oswal Securities said. Ranbaxy’s 15-month earnings (Jan 2013-March 2014) from Russia was Rs 650 crore. But some compa nies may escape the rouble depreciation consequence net-net, as their loss will be offset by rupee depreciation (against the dollar).

But some analysts say the impact may not be large. “It’s unlikely to impact Dr Reddy’s profitability much as it earns only 15% of its sales (FY2014) from Russia, says Sarabjit Kour Nangra, VP research (pharma), Angel Broking.


Pharma Cos To Take A Hit As Govt Caps 108 Drug Prices –

Govt Caps Prices of 108 More Medicines


India‘s pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.  Drugmakers protested the move as prices of generic drugs are alerady much lower in India compared to other markets.

The notice by the National Pharmaceutical Pricing Authority (NPPA), published on its website coincides with moves by the health ministry to widen the list of essential medicines which will be subject to a price cap, people familiar with the matter told Reuters last month.

India last year raised the number of drugs that are subject to price controls to cover up to 30 per cent of the total medication sold in the country, according to industry officials. The new price caps took effect on July 11, an NPPA official said. Injeti Srinivas, who took charge as NPPA’s chairman in June, was not immediately available for comment.

Below is the impact of Ceiling Price declared products basket  based on MRP– overall for top companies based on June 2014 data

Drugmakers Slam Decision
The drug pricing regulator’s decision, aimed at improving affordability, was slammed by the drugmakers in India, where prices of generic drugs sold are already low compared with international markets.

India, an emerging market for drugmakers, last year raised the number of drugs that are subject to price control to cover up to 30 percent of the total medicines sold in the country, according to industry officials.

Pharmaceutical companies and medical bodies have called for revisiting  this decision and help build a more collaborative environment, partnering and engaging with all stakeholders to find sustainable solutions to the healthcare challenges that face our country today.

The pharmaceutical industry seeks stability and predictability in the regulatory environment and our expectation has been reinforced by assurances from several departments and officials in the Ministry of Chemicals and Fertilisers. They committed to a consultative process with all stakeholders and transparent, market-based pricing caps on essential medicines, with continued flexibility in the pricing of other medicines. We were assured that there would be no volatility in pricing, that Government would work in close consultation with industry and that the intent was to build trust and cooperation.
However, NPPA’s arbitrary and unilateral action runs contrary to all these sentiments. It has shocked the industry and will be detrimental to the investment climate for market expansion, brand building and employment generation in the future, said Dr Shailesh Ayyangar, President- OPP (Organisation of Pharmaceutical Producers o India), in a statement.

“While we appreciate the government’s intent to improve affordability … the manner and method in which this unilateral decision has been taken, is untenable,” Sanofi India’s Managing Director Shailesh Ayyangar said on Monday.

“We are evaluating the impact of this order on our ability to continue offering our products with the same value proposition,” he said,

The NPPA said it was using its right to fix the prices of any drug “in extraordinary circumstances, if it considers necessary so to do in public interest”.

In a research note on Sunday, analysts at Nomura named Sanofi India, the Indian unit of French drugmaker Sanofi SA, Abbott Healthcare Private Ltd, a unit of US-based Abbott Laboratories, and local firm Ranbaxy as among companies that will be most impacted by the price cap.

The companies did not immediately respond to a Reuters request for comment.

“Though the impact is limited, the move by the NPPA has increased the risk of additional controls in the future,” Nomura analysts Saion Mukherjee and Lalit Kumar wrote in the report.

Abbott and Ranbaxy did not respond to requests for comment.

“Though the impact is limited, the move by the NPPA has increased the risk of additional controls in the future,” Nomura analysts Saion Mukherjee and Lalit Kumar wrote in the report.

The drug pricing regulator invoked a rarely-used provision that gives the agency the right to fix the prices of any drug “in extraordinary circumstances, if it considers necessary so to do in public interest”.

A spokesman for Dr. Reddy’s Laboratories Ltd, India’s second-largest drugmaker by sales, said the company was assessing its next step, but does not expect the price caps to have a material impact on its financial results.

“At an industry level, there may be some discussion to see whether one can challenge this,” he said but added that the regulator’s decision to invoke the “public interest” provision would make the options limited.


Sun Pharma-Ranbaxy Deal Has Some Important Lessons

Over the last few days, media has been abuzz with the news of Sun Pharma’s $4-billion acquisition of Ranbaxy.

Given the fact that it is the second largest acquisition in the Indian pharmaceutical sector till date, it is not surprising that everybody is fixated on the sheer size of the deal.

But if you look beyond the fancy valuation, this courageous move by Sun Pharma founder Diliip Shanghvi to buy out the beleaguered Ranbaxy from Daiichi Sankyo has some important lessons for everybody.

1. Creating value

Dilip Shanghvi, a first-generation entrepreneur, has not rested on his laurels after building India’s most valuable pharmaceutical company.

By acquiring Ranbaxy, Sun Pharma has taken a giant leap to emerge as the fifth largest speciality generic drug maker globally and the largest in India.

An entity that started off with a single manufacturing plant in 1983 is now poised to have operations in 65 countries, 47 manufacturing facilities across five continents and a global portfolio of specialty and generic products once the Ranbaxy deal closes.

Not only that, Sun Pharma’s revenue will almost double to $4.3 billion.

2. Restoring lost glory

Ranbaxy’s acquisition by Sun Pharma will result in a formidable generics power house, which could help restore India’s reputation as a reliable provider of good quality, affordable medicines for patients the world over.

Having successfully dealt with regulatory issues at its US subsidiary Caraco Pharmaceuticals, I believe Sun Pharma is better placed than Ranbaxy’s erstwhile Japanese owners in tackling the various instances of regulatory non-compliance in the company.

Both Sun Pharma and Ranbaxy have formidable track records in the US market, so the pooling of their manufacturing, distribution and regulatory strengths could be a crucial step forward in regaining the market share the Indian pharma industry has lost in the aftermath of the recent quality controversy.

3. Living up to reputation

Dilip has an enviable reputation of acquiring distressed assets and turning them around.

He has previously succeeded in reviving the fortunes of Israel-based Taro Pharmaceutical.

If Dilip can give Ranbaxy a fresh lease of life, it will cement his reputation as a turnaround artist par excellence.

4. Unshackling pharma M&As

The Sun Pharma-Ranbaxy deal also shows that there is no need to ring fence the Indian pharma industry though restrictive FDI policies. The domestic pharma industry can compete with pharma MNCs when it comes to M&As.

As an Economic Times editorial put it succinctly: “The current deal shows that what MNCs can do, Indian companies can do as well, to achieve scale.”

The Sun-Ranbaxy merger stands a better chance of being successful due to the inherent similarity of their business models and work cultures.

The Ranbaxy deal has been structured in such a way that Daiichi Sankyo will become thesecond largest shareholder in Sun Pharma. Instead of seeing Daiichi Sankyo as a threat, Dilip sees the Japanese company as an ally in realizing Sun Pharma’s global ambitions.

Depending on the business imperatives, founders of pharma companies should be free to monetize their assets just like most of the other sectors.

5. Doing things differently

Where others had written off Ranbaxy because of the company’s quality and regulatory non-compliance problems in the US, Sun Pharma decided to take a contrarian view.

In fact, Sun Pharma has succeeded in being an outlier in the Indian pharma industry because of Dilip’s penchant of doing things differently.

If there’s one big lesson that a budding entrepreneur can take away from the Sun Pharma-Ranbaxy deal it is that good entrepreneurs need to constantly look for opportunities, whether they are just getting started or already in business. And when opportunities come, one will need to take a calculated risk.

Pharma industry to see lower growth this fiscal: IDMA president

The pharmaceutical industry in the country, which has been recording a growth of around 15% over past few years, would see a lower growth of 10-12% this fiscal year, owing to the current economic slowdown and the new Drug Price Control Order (DPCO), expects the pharmaceutical manufacturers’ association.

With the prospects increasing in exports, the association is planning to tie up with its counterparts in various countries including China, Japan and Britain, said S V Veeramani, who recently took over as the president of Indian Drug Manufacturers’ Association (IDMA).

“The industry has seen a mere growth of one% in August and a negative growth in September, in 2013. However, it bounced back to six% growth in November and nine% in December,” he said. The growth in November and December could also be attributed to the season, which generally see an increase in sales of antibiotics and some of the other medicines as there would be an increase in number of minor health issues due to the climate change.

The industry has seen a growth of 14.9% in 2011 and 16.6% in 2012, he said quoting reports from AIOCD Pharmasofttech AWACS, a pharmaceutical market research company of the traders’ organisation AIOCD. While the industry has seen a recovery from the slowdown, the growth for the financial year would reflect a drop of 2-3%.

The new DPCO has restricted price of 348 essential medicines based on market linked pricing and putting a cap for increase in price based on the wholesale price index of the drugs. According to the report, the industry has seen a loss of Rs 140-150 crore per month in the first couple of months due to this, he said.

However, the country continue to be a good opportunity with the health allocation in budgets going up, increased penetration of insurance and public awareness on importance of health.

The association is also looking at supporting more of its members to start exports, with the opportunities for exports are also growing.  It is entering into tie up with the China Pharmaceutical Industry Association (CPIA), IDMA’s counterpart in China, for collaboration starting with information sharing and interaction and removing bilateral trade frictions.

The tie up could eventually lead companies in both the countries work together, and even getting into joint venture where the strengths of the companies could be used for mutual benefit.  Similar discussions are going on with Osaka Pharmaceutical Manufacturers Association (OPMA) and plans are to start discussions with British Generic Manufacturers Association (BGMA), which represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.